Product Information
DURAFLU 325-20-200-60 MG TAB is a generic product labeled by Poly Pharmaceuticals, Inc., priced at $0.9041 per EA under NDC 50991053501. Its NADAC has been published 325 times since May 18, 2016.
DURAFLU 325-20-200-60 MG TAB
ACETAMINOPHEN, DEXTROMETHORPHAN HBr, GUAIFENESIN, PSEUDOEPHEDRINE HClStrength
325; 20; 200; 60 mg/1; mg/1; mg/1; mg/1
Manufacturer
Poly Pharmaceuticals, Inc.NDC
50991053501
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
10/22/2025
Active Ingredients
ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
10/1/2015
Pharmacological Classes
Price Statistics
The NADAC for DURAFLU 325-20-200-60 MG TAB has been published 325 times since May 18, 2016, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9041 per EA |
|---|---|
| All-time high | $0.9988 (Mar 14, 2018) |
| All-time low | $0.8919 (Jan 18, 2017) |
| 52-week high | $0.9042 |
| 52-week low | $0.9041 |
| Median price | $0.9041 |
| Average price | $0.9125 |
| Largest weekly change | +11.8% (Feb 21, 2018) |
| Weeks tracked | 325 |
| Tracking since | May 18, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ACETAMINOPHEN, DEXTROMETHORPHAN HBr, GUAIFENESIN, PSEUDOEPHEDRINE HCl market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Poly Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ACETAMINOPHEN, DEXTROMETHORPHAN HBr, GUAIFENESIN, PSEUDOEPHEDRINE HCl market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Expectorant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DURAFLU 325-20-200-60 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DURAFLU 325-20-200-60 MG TAB, manufactured by Poly Pharmaceuticals, Inc., is $0.9041 per EA (NDC 50991053501), effective Sep 30, 2026.
How has the price of DURAFLU 325-20-200-60 MG TAB changed over time?
Over the history we have for it, the NADAC for DURAFLU 325-20-200-60 MG TAB has held within roughly two percent of its current level. It has been tracked across 325 weekly CMS publications since May 18, 2016.
What are the highest and lowest recorded NADAC prices for DURAFLU 325-20-200-60 MG TAB?
Since May 18, 2016, the NADAC for DURAFLU 325-20-200-60 MG TAB has ranged from a low of $0.8919 (Jan 18, 2017) to a high of $0.9988 (Mar 14, 2018), with a median of $0.9041 per EA.
Are there cheaper alternatives to DURAFLU 325-20-200-60 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of DURAFLU 325-20-200-60 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DURAFLU 325-20-200-60 MG TAB?
DURAFLU 325-20-200-60 MG TAB (NDC 50991053501) is labeled by Poly Pharmaceuticals, Inc., and CMS classifies it as a generic product.